Protalix BioTherapeutics, Inc. (PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., reported positive initial top line results from the Phase 3 study of pegunigalsidase alfa (PRX-102), dubbed Balance, for the proposed treatment of Fabry disease. The Balance study of PRX-102 in Fabry patients with impaired renal function evaluates the safety and efficacy of 1 mg/kg of PRX-102 dosed every two weeks compared to agalsidase beta (Fabrazyme).
The primary endpoint of the interim analysis is the comparison of mean annualized changes of the eGFR (CKD-EPI) after completion of at least 12 months of treatment between the two treatment arms.
The initial top-line results show that the lower boundary of the confidence interval for the mean difference between the two treatments was below the non-inferiority margin pre-specified for this interim analysis in the ITT analysis set and above such limit in the PP analysis set.
Based on the 12-month data from the Balance study, along with positive data from Phase 3 Bright and Bridge studies, Protalix and Chiesi plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA).
Protalix and Chiesi also plan to submit a Type-A meeting request with the FDA to discuss the path for approval of PRX-102.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.